Physician profile
Hal M Roseman
NPI 1366541302
$78,791.61
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $4,009 · 2021: $347 · 2022: $58.81.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63,356.90 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $7,714.49 | 2019 | |
| Amgen INC. | $3,721.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $3,346.36 | 2019-2022 | |
| Esperion Therapeutics, INC. | $279.23 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $217.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $94.85 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.62 | 2021 | |
| Bardy Diagnostics, INC. | $16.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.60 | 2022 | |
| Pfizer INC. | $12.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$108,006.38 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Roseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.